In 2025 a landmark study was published, which found there was widespread misleading information in social media posts about common medical tests targeted at healthy people, such as full-body MRIs, anti-Müllerian hormone (AMH) tests and testosterone tests.

We are working with The University of Sydney’s social media team, to try and address some of that misleading information, by offering evidence-based information.* Academic presenters of our social media posts, include Dr Brooke Nickel, Dr Melody Taba, and Dr Josh Zadro, all from The University of Sydney.

Full-Body MRI for Healthy People

2025 RANZCR:  The peak professional body of radiologists, the Royal Australian and New Zealand College of Radiologists’ 2025 Position Statement “does not recommend” the use of whole-body MRIs (Magnetic Resonance Imaging) for low-risk or asymptomatic people, which you can read here, because “currently there is no evidence that demonstrates significant improvement in health outcomes.” In addition, the “risks of performing whole body MRI on these asymptomatic patients are significant. Incidental findings can lead to significant and unnecessary patient anxiety, further investigation (including biopsy) and substantial downstream healthcare costs.” And importantly, “False reassurance from whole body MRI has the potential for significant negative health outcomes.”

2025 ASMIRT: The President of the Australian Society of Medical Imaging and Radiation Therapy also in 2025 warned against asymptomatic people having whole body MRIs, saying “False positives and indeterminate findings are a frequent result of whole-body MRI. This can lead to further costly and potentially unnecessary investigations into conditions that are ultimately benign."

2023 ACR: The American College of Radiology  Statement in 2023 similarly does not recommend whole-body MRIs for healthy people and is concerned it “will lead to the identification of numerous non-specific findings that will not ultimately improve patients' health but will result in unnecessary follow-up testing and procedures, as well as significant expense.”

2025 Wiser Healthcare & RANZCOG:  Evidence-based information produced by Wiser Healthcare and  endorsed by the Royal Australian and New Zealand College of Obstetricians and Gynaecologists is available here, and states that the AMH test results are “not a reliable sign of a woman’s fertility”.  2024 research published in the journal Human Reproduction, and led from the University of Sydney, has shown that when women are informed of the evidence about AMH, they have lower interest in having the test. Your Fertility is a government-funded website with evidence-based information about fertility, related health conditions and infertility resources.

2025 F&S: An editorial in 2025 in the journal Fertility and Sterility also confirmed that “routine measurement of AMH in young women for counselling them about their fecundity is fundamentally flawed.”

2020 ASRMPC: The American Society for Reproductive Medicine  Practice Committee state in their 2020 publication that an AMH test “should not be used as a fertility test”as ovarian reserve cannot predict reproductive potential.

2022 BC Guidelines: A Testosterone testing protocol from a Canadian provincial government authority in British Columbia updated in 2022 states that testing for testosterone “is not recommended” in asymptomatic men and women.

2022 FiE:  A review  in the journal Frontiers in Endocrinology in 2022, from a leading global expert, warns of the “epidemic of overprescribing of testosterone in the last few decades” and states that the screening of healthy men “is not recommended” by “even the most enthusiastic of guidelines.”

2016 ESA: The Endocrine Society of Australia position statement in 2016 on male hypogonadism states that  “there are no convincing data that healthy ageing necessarily results in a lowering of serum testosterone level to an extent that constitutes a clinical deficiency” and warns that using testosterone long term carries side effects, including increased risks of impaired fertility, balding, and weight gain.